Scan to Download
One power score. Smarter investment decisions
Lexeo Therapeutics Inc
LXEO5.460USD
+0.100+1.87%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
5.400USD+5.400After-hours 09/19, 20:00 (ET)
294.83MMarket Cap
LossP/E TTM
Lexeo Therapeutics Inc
5.460
+0.100+1.87%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Total revenue
----
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--531.00K
--37.00K
--85.55K
Revenue
----
----
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--531.00K
--37.00K
--85.55K
Operating expenses
30.31%30.69M
45.14%33.80M
82.86%27.38M
55.59%31.54M
68.52%23.55M
20.74%23.29M
-1.47%14.97M
12.55%20.27M
-8.95%13.97M
53.04%19.29M
--15.20M
--18.01M
--15.35M
--12.60M
R&D expenses
-11.11%14.72M
9.08%17.17M
123.70%18.37M
35.82%23.42M
47.38%16.56M
-4.23%15.74M
-27.90%8.21M
12.26%17.25M
-8.40%11.24M
62.01%16.44M
--11.39M
--15.36M
--12.27M
--10.15M
Depreciation, depletion, and amortization
2.82%510.00K
5.25%501.00K
6.33%521.00K
10.65%509.00K
11.19%496.00K
6.50%476.00K
10.11%490.00K
34.50%460.00K
26.98%446.06K
6568.70%446.94K
--445.00K
--342.00K
--351.30K
--6.70K
Operating profit
-30.31%-30.69M
-45.14%-33.80M
-82.86%-27.38M
-55.59%-31.54M
-68.52%-23.55M
-20.74%-23.29M
1.47%-14.97M
-15.96%-20.27M
8.73%-13.97M
-54.09%-19.29M
---15.20M
---17.48M
---15.31M
---12.52M
Net non-operating interest income (expenses)
Non-operating interest income
-46.00%1.27M
-27.20%1.20M
32.94%1.47M
328.69%2.09M
297.97%2.35M
140.15%1.65M
63.02%1.10M
7.02%488.00K
233.33%590.00K
3877.87%687.50K
--676.00K
--456.00K
--177.00K
--17.28K
Non-operating interest expense
-28.57%25.00K
0.00%37.00K
-40.00%30.00K
-32.69%35.00K
-33.96%35.00K
-25.95%37.00K
-10.71%50.00K
79.31%52.00K
488.89%53.00K
--49.97K
--56.00K
--29.00K
--9.00K
--0.00
Gains from sale of securities
--3.39M
----
428.57%23.00K
----
----
-10.60%-5.00K
---7.00K
--1.00K
---3.00K
---4.52K
----
--0.00
----
----
Special income (expenses)
---34.00K
---12.00K
----
----
----
----
---258.00K
---272.00K
----
----
----
--0.00
----
----
Other non-operating income (expenses)
-1300.00%-14.00K
---4.00K
--0.00
---3.00K
---1.00K
----
----
----
----
----
--0.00
----
--0.00
--146.00
Income before tax
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Income tax
----
----
----
----
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Income after tax
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income from continuous operations
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income attributable to controlling interests
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Net income attributable to common shareholders
-22.91%-26.10M
-50.61%-32.66M
-82.73%-25.92M
-46.65%-29.49M
-58.01%-21.24M
-16.21%-21.68M
2.68%-14.19M
-17.90%-20.11M
11.24%-13.44M
-49.24%-18.66M
---14.58M
---17.05M
---15.14M
---12.50M
Basic earnings per share
6.91%-0.60
-27.26%-0.99
-36.24%-0.78
-9.42%-0.89
-18.11%-0.64
-2.46%-0.77
2.67%-0.58
-17.90%-0.82
11.24%-0.54
-49.24%-0.76
---0.59
---0.69
---0.61
---0.51
Diluted earnings per share
6.91%-0.60
-27.26%-0.99
-36.24%-0.78
-9.42%-0.89
-18.11%-0.64
-2.46%-0.77
2.67%-0.58
-17.90%-0.82
11.24%-0.54
-49.24%-0.76
---0.59
---0.69
---0.61
---0.51
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
--
--
--
--
--
